docetaxel anhydrous has been researched along with loperamide in 3 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (loperamide) | Trials (loperamide) | Recent Studies (post-2010) (loperamide) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 1,358 | 196 | 488 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | loperamide (IC50) |
|---|---|---|---|
| Cocaine esterase | Homo sapiens (human) | 5.7 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 3.005 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.5 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 9.27 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2 | |
| Histamine H2 receptor | Homo sapiens (human) | 3.081 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 2.202 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.0014 | |
| D(3) dopamine receptor | Homo sapiens (human) | 1.337 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.896 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 3.125 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 4.105 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.033 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 0.239 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.628 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Armand, JP; Couteau, C; Goncalves, E; Terret, C; Yakendji, K | 1 |
| Kim, HK; Kim, MJ; Lee, HY; Lee, YH | 1 |
2 review(s) available for docetaxel anhydrous and loperamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
1 trial(s) available for docetaxel anhydrous and loperamide
| Article | Year |
|---|---|
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
1 other study(ies) available for docetaxel anhydrous and loperamide
| Article | Year |
|---|---|
Secondary prophylaxis of docetaxel induced diarrhea with loperamide: case report.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Drug Therapy, Combination; Humans; Loperamide; Lung Neoplasms; Male; Neoplasm Staging; Taxoids; Tomography, X-Ray Computed | 2013 |